Lodosyn, Stalevo(carbidopa)
Corbilta, Dhivy, Duopa, Levodopa/Carbidopa/Entacapone, Lodosyn, Numient, Rytary, Sinemet, Stalevo (carbidopa) is a small molecule pharmaceutical. Carbidopa was first approved as Lodosyn on 1982-01-01. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against aromatic-L-amino-acid decarboxylase.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Lodosyn (generic drugs available since 1992-08-28)
CombinationsDhivy, Duopa, Rytary, Sinemet, Stalevo (generic drugs available since 1992-08-28, discontinued: Carbilev, Parcopa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carbidopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LODOSYN | Aton Pharma | N-017830 RX | 1982-01-01 | 1 products, RLD, RS |
Carbidopa
+
Entacapone
+
Levodopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STALEVO 75 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
| STALEVO 125 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
| STALEVO 200 | Orion Pharma | N-021485 RX | 2007-08-02 | 1 products, RLD, RS |
| STALEVO 50 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD, RS |
| STALEVO 100 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
| STALEVO 150 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
Carbidopa
+
Levodopa
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Carbidopa / Levodopa, Dhivy, Avion Pharms | |||
| 11033521 | 2039-03-28 | DP | U-219, U-3304, U-3305 |
| 11439613 | 2039-03-28 | U-3557 | |
| Carbidopa / Levodopa, Rytary, Impax Labs Inc | |||
| 8377474 | 2028-12-26 | DP | U-219, U-1645 |
| 8454998 | 2028-12-26 | DP | U-219, U-1645, U-1646, U-1647, U-1649 |
| 8557283 | 2028-12-26 | DP | U-219, U-1645 |
| 9089607 | 2028-12-26 | DP | U-1645, U-1720 |
| 9089608 | 2028-12-26 | DP | |
| 9463246 | 2028-12-26 | DP | U-219 |
| 9533046 | 2028-12-26 | DP | U-219 |
| 9901640 | 2028-12-26 | DP | U-219 |
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J7340 | Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml |
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 31 | 29 | 24 | 16 | 7 | 102 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 2 | 2 | 2 | 1 | 6 |
| Depression | D003863 | F33.9 | — | — | — | 3 | 1 | 4 | |
| Back pain | D001416 | HP_0003418 | M54 | — | 2 | — | 1 | — | 3 |
| Dyskinesias | D020820 | G24 | — | — | 1 | 1 | — | 2 | |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | — | 1 | — | 1 | |
| Anhedonia | D059445 | R45.84 | — | — | — | 1 | — | 1 | |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | — | 1 |
| Neurologic gait disorders | D020233 | R26.1 | — | — | — | 1 | — | 1 | |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 1 | 5 | 1 | — | — | 6 | |
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | 2 | 2 | — | — | 3 | |
| Familial dysautonomia | D004402 | Orphanet_1764 | G90.1 | — | 1 | 1 | — | — | 2 |
| Amblyopia | D000550 | H53.00 | — | 1 | 1 | — | — | 2 | |
| Stroke rehabilitation | D000071939 | — | — | 1 | — | — | 1 | ||
| Broca aphasia | D001039 | — | 1 | 1 | — | — | 1 | ||
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | — | 1 | 1 | — | — | 1 | |
| Orthostatic intolerance | D054971 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 5 | — | — | — | 5 |
| Multiple system atrophy | D019578 | 2 | 1 | — | — | — | 2 | ||
| Acute pain | D059787 | R52 | — | 2 | — | — | — | 2 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 2 |
| Chronic pain | D059350 | HP_0012532 | — | 2 | — | — | — | 2 | |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | 1 | — | — | — | 1 |
| Retinitis pigmentosa | D012174 | HP_0000580 | H35.52 | — | 1 | — | — | — | 1 |
| Oculocutaneous albinism | D016115 | E70.32 | — | 1 | — | — | — | 1 | |
| Albinism | D000417 | E70.3 | — | 1 | — | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | — | — | — | — | 8 | ||
| Pure autonomic failure | D054970 | 2 | — | — | — | — | 2 | ||
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | I95.1 | 1 | — | — | — | — | 1 | |
| Dementia | D003704 | F03 | 1 | — | — | — | — | 1 | |
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | — | — | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 1 | — | — | — | — | 1 |
| Smoking | D012907 | EFO_0003768 | F17 | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep wake disorders | D012893 | G47 | — | — | — | — | 1 | 1 | |
| Parkinsonian disorders | D020734 | HP_0001300 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CARBIDOPA |
| INN | carbidopa |
| Description | Carbidopa (anhydrous) is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug and a dopaminergic agent. It is a member of hydrazines, a monocarboxylic acid and a member of catechols. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O |
Identifiers
| PDB | — |
| CAS-ID | 38821-49-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200748 |
| ChEBI ID | 3395 |
| PubChem CID | 34359 |
| DrugBank | DB00190 |
| UNII ID | KR87B45RGH (ChemIDplus, GSRS) |
Target
Agency Approved
DDC
DDC
Alternate
No data
Variants
Clinical Variant
No data
Financial
Sinemet - Organon
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Rytary - Amneal Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,447 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
937 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more